Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 6Astrocytoma 4Oligodendroglioma 2Recurrence 1Pathologic Processes 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Follicular 1Healthy Adult Participants 1Disease Attributes 1Brain Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × vorasidenib × Clear all
NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡